The text has been copied to the clipboard
Back
Development of a Novel Human Cell-Derived Tissue-Engineered Heart Valve for Transcatheter Aortic Valve Replacement: an In Vitro and In Vivo Feasibility Study.
Journal article

Development of a Novel Human Cell-Derived Tissue-Engineered Heart Valve for Transcatheter Aortic Valve Replacement: an In Vitro and In Vivo Feasibility Study.

  • Lintas V Institute for Regenerative Medicine (IREM), University of Zurich, Center for Therapy Development/GMP, Zurich, Switzerland.
  • Fioretta ES Institute for Regenerative Medicine (IREM), University of Zurich, Center for Therapy Development/GMP, Zurich, Switzerland.
  • Motta SE Institute for Regenerative Medicine (IREM), University of Zurich, Center for Therapy Development/GMP, Zurich, Switzerland.
  • Dijkman PE Institute for Regenerative Medicine (IREM), University of Zurich, Center for Therapy Development/GMP, Zurich, Switzerland.
  • Pensalfini M Institute for Mechanical Systems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.
  • Mazza E Institute for Mechanical Systems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.
  • Caliskan E Clinic for Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Rodriguez H Clinic for Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Lipiski M Clinic for Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Sauer M Clinic for Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Cesarovic N Clinic for Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Hoerstrup SP Institute for Regenerative Medicine (IREM), University of Zurich, Center for Therapy Development/GMP, Zurich, Switzerland.
  • Emmert MY Institute for Regenerative Medicine (IREM), University of Zurich, Center for Therapy Development/GMP, Zurich, Switzerland. maximilian.emmert@usz.ch.
Show more…
  • 2018-08-15
Published in:
  • Journal of cardiovascular translational research. - 2018
Clinical translation
Off-the-shelf
Regenerative medicine
Tissue engineering
Tissue-engineered heart valve
Transcatheter aortic valve replacement
Animals
Aortic Valve
Bioprosthesis
Cells, Cultured
Echocardiography, Doppler, Color
Echocardiography, Three-Dimensional
Extracellular Matrix
Feasibility Studies
Heart Valve Prosthesis
Hemodynamics
Humans
Models, Animal
Prosthesis Design
Sheep, Domestic
Time Factors
Tissue Engineering
Tissue Scaffolds
Tomography, X-Ray Computed
Transcatheter Aortic Valve Replacement
English Transcatheter aortic valve replacement (TAVR) is being extended to younger patients. However, TAVR-compatible bioprostheses are based on xenogeneic materials with limited durability. Off-the-shelf tissue-engineered heart valves (TEHVs) with remodeling capacity may overcome the shortcomings of current TAVR devices. Here, we develop for the first time a TEHV for TAVR, based on human cell-derived extracellular matrix and integrated into a state-of-the-art stent for TAVR. The TEHVs, characterized by a dense acellular collagenous matrix, demonstrated in vitro functionality under aortic pressure conditions (n = 4). Next, transapical TAVR feasibility and in vivo TEHV functionality were assessed in acute studies (n = 5) in sheep. The valves successfully coped with the aortic environment, showing normal leaflet motion, free coronary flow, and absence of stenosis or paravalvular leak. At explantation, TEHVs presented full structural integrity and initial cell infiltration. Its long-term performance proven, such TEHV could fulfill the need for next-generation lifelong TAVR prostheses.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/185254
Export to…
JSON data
Dublin Core
BibTeX
RIS (Zotero, …)
Statistics
Document views: 77 File downloads: